var data={"title":"Leucovorin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Leucovorin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6443?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">see &quot;Leucovorin: Drug information&quot;</a> and <a href=\"topic.htm?path=leucovorin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Leucovorin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11508393\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lederle Leucovorin;</li>\n      <li>Leucovorin Calcium Injection;</li>\n      <li>Leucovorin Calcium Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059685\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Methotrexate</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Folic Acid Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26536218\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pyrimethamine hematologic toxicity, prevention (Congenital toxoplasmosis): Note:</b> Leucovorin is administered in combination with pyrmethamine and sulfadiazine in the treatment of congenital toxoplasmosis; leucovorin should continue for 1 week after pyrimethamine is discontinued (DHHS [pediatric], 2013). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-exposed/-positive: IM, Oral: 10 mg with every pyrimethamine dose; treatment duration: 12 months (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HIV-exposed/-positive: IM, Oral: 10 mg three times weekly for 12 months (McAuley, 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059679\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">see &quot;Leucovorin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing in pediatric patients presented in mg, mg/m<sup>2</sup> and mg/kg; use caution. Because oral absorption is saturable at doses &gt;25 mg, administration of single oral doses &gt;25 mg is not recommended (convert to parenteral therapy); also consider parenteral administration instead of oral in patients with GI toxicity, nausea, or vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist (eg, pyrimethamine, trimethoprim) overdose:</b> Infant, Children, and Adolescents: Oral: 5 to 15 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folinic-acid dependent seizures:</b> Very limited data available: Infants and Children: Oral: Initial: 2.5 to 5 mg twice daily; may gradually increase for seizure recurrence; doses up to 8 mg/kg/day (ie, 25 mg three times daily) have been reported. Dosing based on small case series and case reports in patients with refractory seizures who were on multiple anticonvulsants with or without pyridoxine (Cloherty 2012; Djukic 2007; Frye 2003; Gallagher 2009; Hyland 1995; Nicolai 2006; Torres 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Megaloblastic anemia secondary to folate deficiency:</b> Infants, Children, and Adolescents: IM, IV: &le;1 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate rescue:</b> Infants, Children, and Adolescents: Initial: Oral, IM, IV: 15 mg (~10 mg/m<sup>2</sup>) every 6 hours; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 <b>g</b>/m<sup>2</sup> IV over 4 hours). Leucovorin (and hydration and urinary alkalinization) should be continued and/or adjusted until the methotrexate level is &lt;0.05 micromolar (5 x 10<sup>-8</sup> M). Adjust dose as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i> Oral, IM, IV: 15 mg every 6 hours for 10 doses beginning 24 hours after the start of methotrexate infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Oral, IM, IV: Continue leucovorin calcium 15 mg every 6 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level &ge;50 micromolar at 24 hours, or &ge;5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i> IV: 150 mg every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate overexposure:</b> Limited data available: Infants, Children, and Adolescents: Leucovorin nomogram dosing for high-dose methotrexate overexposure (generalized dosing derived from reference nomogram figures, refer to each reference (Bleyer, 1978; Bleyer, 1981; Widemann, 2006) or protocol-specific nomogram for details):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 24 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;100 micromolar at ~24 hours, leucovorin is initially dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 to &lt;100 micromolar at 24 hours, leucovorin is initially dosed at 100 mg/m<sup>2</sup> IV every 3 or 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin is initially dosed at 10 mg/m<sup>2</sup> IV or orally every 3 or 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 48 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;100 micromolar at 48 hours, leucovorin is dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 to &lt;100 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 6 hours <b>or</b> 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>At 72 hours:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of &ge;10 micromolar at 72 hours, leucovorin is dosed at 100 to 1,000 mg/m<sup>2</sup> IV every 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally every 3 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If serum creatinine is increased more than 50% above baseline, increase the standard leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours, then adjust according to methotrexate levels above.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Follow methotrexate levels daily, leucovorin may be discontinued when methotrexate level is &lt;0.1 micromolar; some have suggested &lt;0.08 micromolar (8 x 10<sup>-8</sup> M) is preferable (Bleyer, 1978)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methotrexate overdose (inadvertent)</b> (begin as soon as possible after overdose): Infants, Children, and Adolescents: Oral, IM, IV: 10 mg/m<sup>2</sup>/dose every 6 hours until the methotrexate level is &lt;0.01 micromolar. If serum creatinine is increased more than 50% above baseline 24 hours after methotrexate administration, if 24 hour methotrexate level is &gt;5 micromolar, or if 48 hour methotrexate level is &gt;0.9 micromolar, increase leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours until the methotrexate level is &lt;0.01 micromolar.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Do not administer leucovorin intrathecally; use of intrathecal leucovorin is not advised (Jardine, 1996; Smith, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Megaloblastic anemia secondary to congenital deficiency of dihydrofolate reductase; treatment:</b> Infants, Children, and Adolescents: IM, Oral: 3 to 6 mg/day (Nelson, 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pyrimethamine hematologic toxicity, prevention:</b> Leucovorin is administered in combination with pyrmethamine and other medications in the treatment of toxoplasmosis; dosing varies with disease process and regimen; consult pyrimethamine specific monograph for additional details; duration of therapy varies based on disease state; however, leucovorin should continue for 1 week after pyrimethamine is discontinued (DHHS [pediatric], 2013); usual regimens include:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxoplasmosis (<i>Toxoplasma gondii</i>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Congenital toxoplasmosis: Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IM, Oral: 10 mg with every pyrimethamine dose; treatment duration: 12 months (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: IM, Oral: 10 mg three times weekly for 12 months (McAuley, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acquired infection:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: Infants, Children, and Adolescents: Acute induction: Oral: 10 to 25 mg once daily for &ge;6 weeks (DHHS, 2014; DHHS [pediatric], 2013). <b>Note:</b> In adolescents, leucovorin may be increased to 50 to100 mg/day in divided doses in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression) (DHHS, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: Chorioretinitis: Infants, Children, and Adolescents: Oral: 10 to 20 mg three times weekly (McAuley, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Primary:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children: Oral: 5 mg once every 3 days (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: Oral: 25 mg once weekly (with pyrimethamine and dapsone) <b>or</b> 10 mg once daily (with pyrimethamine and atovaquone) (DHHS, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hematopoietic stem cell transplantation recipients:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children: Oral: 5 mg every 3 days; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (Tomblyn, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: Oral: 10 to 25 mg once daily; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (Tomblyn, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Secondary: HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children: Oral: 5 mg once every 3 days (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: Oral: 10 to 25 mg once daily <b>or</b> 10 mg once daily (DHHS, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pneumocystis jirovecii</i> pneumonia (PCP): Prophylaxis (primary and secondary): Adolescents: Oral: 25 mg once weekly <b>or</b> 10 mg once daily (DHHS, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Isosporiasis (<i>Isospora</i> belli):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment, acute infection:</i> Infants, Children, and Adolescents: Oral: 10 to 25 mg once daily (DHHS, 2014; DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prophylaxis, secondary: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: Oral: 10 to 25 mg once daily (DHHS [pediatric], 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Oral: 5 to10 mg once daily (DHHS, 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methanol toxicity; cofactor therapy:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 mg/kg (maximum dose: 50 mg) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (Barceloux, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult: <b>Note:</b> Because oral absorption is saturable at doses &gt;25 mg, administering single oral doses &gt;25 mg is not recommended (convert to parenteral therapy); also consider parenteral administration instead of oral in patients with GI toxicity, nausea, or vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Colorectal cancer:</b> IV: 200 mg/m<sup>2</sup>/day over at least 3 minutes for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil) <b>or</b> 20 mg/m<sup>2</sup>/day for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil). <b>Note:</b> Multiple leucovorin-containing regimens are available for the treatment of colorectal cancer. Refer to appropriate literature/guidelines for additional details.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folic acid antagonist (eg, trimethoprim, pyrimethamine) overdose:</b> Oral: 5 to 15 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Folate-deficient megaloblastic anemia:</b> IM, IV: &le;1 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>High-dose methotrexate-rescue:</b> Initial: Oral, IM, IV: 15 mg (~10 mg/m<sup>2</sup>); start 24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses, until methotrexate level is &lt;0.05 micromolar. Adjust dose as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i> Oral, IM, IV: 15 mg every 6 hours for 60 hours (10 doses) beginning 24 hours after the start of methotrexate infusion</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Continue leucovorin calcium 15 mg (oral, IM, or IV) every 6 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level &ge;50 micromolar at 24 hours, or &ge;5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i> IV: 150 mg every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromolar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Methotrexate overdose (inadvertent)</b> (begin as soon as possible after overdose): Oral, IM, IV: 10 mg/m<sup>2</sup> every 6 hours until the methotrexate level is &lt;0.01 micromolar. If serum creatinine is increased more than 50% above baseline 24 hours after methotrexate administration, if 24 hour methotrexate level is &gt;5 micromolar, or if 48 hour methotrexate level is &gt;0.9 micromolar, increase leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours until the methotrexate level is &lt;0.01 micromolar.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (Jardine, 1996; Smith, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187344\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg/30 mL (30 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea); 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 15 mg, 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187331\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059689\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: <b>This drug should be given parenterally instead of orally in patients with GI toxicity, nausea, vomiting, and when individual doses are &gt;25 mg.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute; <b>not intended for intrathecal use</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Toxicity to normal tissues may be irreversible if leucovorin is not initiated by ~40 hours after the start of methotrexate. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">As a rescue after folate antagonists: Administer by IV bolus, IM, or orally</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">For the treatment of methanol toxicity, infuse over 30 to 60 minutes (Barceloux 2002)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187359\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for injection: Powder for injection: Store intact vials and reconstituted solution at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light. Solutions reconstituted with bacteriostatic water for injection U.S.P., must be used within 7 days. Solutions reconstituted with SWFI must be used immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection: Prior to dilution, store vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059688\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Rescue agent to diminish the toxicity and counteract the effects of impaired methotrexate elimination or as an antidote for folic acid antagonist overdosage (FDA approved in pediatric patients [age not specified] and adults); has also been used in the treatment of folinic acid responsive seizures. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Rescue agent after high-dose methotrexate treatment in osteosarcoma and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; treatment of megaloblastic anemias due to folic acid deficiency (when oral therapy is not feasible) (FDA approved in pediatric patients [age not specified] and adults); treatment of advanced colorectal cancer (palliative) in combination with fluorouracil (FDA approved in adults); has also been used as rescue agent after high-dose methotrexate treatment in treatment of other cancers; as adjunctive cofactor therapy in methanol toxicity, adjunctive treatment with sulfadiazine and pyrimethamine to prevent hematologic toxicity </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187410\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Leucovorin may be confused with Leukeran, Leukine, LEVOleucovorin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folinic acid may be confused with folic acid</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Folinic acid is an error prone synonym and should not be used</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187407\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Toxicities (especially gastrointestinal toxicity) of fluorouracil are enhanced when used in combination with leucovorin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187350\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Pernicious anemia and other megaloblastic anemias secondary to vitamin B<sub>12</sub>-deficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5524355\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity, including allergic reactions, anaphylactoid reactions, and urticaria have been reported with leucovorin. Because leucovorin is typically administered in combination with other chemotherapy agents, it may be difficult to determine the causative agent for hypersensitivity reactions. In a series of 44 patients with hypersensitivity to leucovorin-containing regimens, hypersensitivity/infusion reaction to leucovorin was confirmed in 5 patients; reactions also occurred with subsequent rechallenge with LEVOleucovorin (Ure&ntilde;a-Tavera 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures or syncope have been reported (rarely) in patients with cancer receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in patients with CNS metastases or other predisposing factors; a causal relationship has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anemias: Leucovorin is inappropriate treatment for pernicious anemia and other megaloblastic anemias secondary to a lack of vitamin B<sub>12</sub>; a hematologic remission may occur while neurologic manifestations progress.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Leucovorin is excreted renally; the risk for toxicities may be increased in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluorouracil: Leucovorin may increase the toxicity of 5-fluorouracil; deaths from severe enterocolitis, diarrhea, and dehydration have been reported (in elderly patients); granulocytopenia and fever have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfamethoxazole-trimethoprim: Combination of leucovorin and sulfamethoxazole-trimethoprim for the acute treatment of PCP in patients with HIV infection has been reported to cause increased rates of treatment failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration route: Parenteral administration may be preferred to oral if vomiting or malabsorption is likely. Because oral absorption is saturable at doses above 25 mg, administering oral doses greater than 25 mg is not recommended (convert to parenteral therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: When doses &gt;10 mg/m<sup>2</sup> are required using the powder for injection, reconstitute using sterile water for injection, not a solution containing benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute. Not intended for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings and precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate overdose: When used for the treatment of a methotrexate overdose, administer IV leucovorin as soon as possible. Monitoring of the serum methotrexate concentration is essential to determine the optimal dose/duration of leucovorin; however, do not wait for the results of a methotrexate level before initiating leucovorin. It is important to adjust the leucovorin dose once a methotrexate level is known. The dose may need to be increased or administration prolonged in situations in which methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of leucovorin therapy. Dose may need increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299583\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187338\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12544&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Systemic). This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Topical): Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing.  Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Tegafur. This effect is associated with the ability of leucovorin or levoleucovorin to enhance the anticancer effects of fluorouracil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187340\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5524281\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1059684\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;\">High-dose methotrexate therapy: CBC with differential; serum creatinine; plasma methotrexate concentrations. Leucovorin is continued until the plasma methotrexate concentration is &lt;0.1 micromolar (1 x 10<sup>-7</sup> molar) or &lt;0.05 micromolar (0.5 x 10<sup>-7</sup> molar) in situations of delayed methotrexate clearance. With 4- to 6-hour high-dose methotrexate infusions, plasma drug values in excess of 50 micromolar (5 x 10<sup>-5</sup> M) and 1 micromolar (10<sup>-6</sup> M) at 24 and 48 hours after starting the infusion, respectively, are often predictive of delayed methotrexate clearance. Monitor fluid and electrolyte status in patients with delayed methotrexate elimination (likely to experience renal toxicity).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used with fluorouracil: CBC with differential, platelets, LFTs, electrolytes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187334\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Leucovorin calcium is a reduced form of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate. Leucovorin actively competes with methotrexate for transport sites, displaces methotrexate from intracellular binding sites, and restores active folate stores required for DNA/RNA synthesis. Stabilizes the binding of 5-dUMP and thymidylate synthetase, enhancing the activity of fluorouracil. When administered with pyrimethamine for the treatment of opportunistic infections, leucovorin reduces the risk for hematologic toxicity (HHS [OI adult 2015]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Methanol toxicity treatment: Formic acid (methanol&rsquo;s toxic metabolite) is normally metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase after being bound to tetrahydrofolate. Administering a source of tetrahydrofolate may aid the body in eliminating formic acid (Barceloux 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187349\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral, IM: Well absorbed </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Intestinal mucosa and hepatically to 5-methyl-tetrahydrofolate (5MTHF; active) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Saturable at oral doses &gt;25 mg; 25 mg (97%), 50 mg (75%), 100 mg (37%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~4 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: ~2 hours; IV: Total folates: 10 minutes; 5MTHF: ~1 hour; IM: Total folates: 52 minutes; 5MTHF: 2.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12807804\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 5 mg/mL oral suspension may be prepared with tablets, Cologel, and a 2:1 mixture of simple syrup and wild cherry syrup. Crush twenty-four 25 mg tablets in a glass mortar and reduce to a fine powder; transfer powder to amber bottle. Add 30 mL Cologel and shake mixture thoroughly. Add a quantity of syrup mixture sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 28 days refrigerated.</p>\n    <div class=\"reference\">Lam MS. Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.<span class=\"pubmed-id\">21275495</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524636\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Leucovorin Calcium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $6.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $24.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (1): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">350 mg (1): $31.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $94.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Leucovorin Calcium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (50): $140.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (12): $100.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (24): $282.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (25): $600.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187352\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acido Folinico/Leucovorina (CL);</li>\n      <li>Antrex (FI, PL, TW);</li>\n      <li>Asovorin (AR);</li>\n      <li>Cafona (TW);</li>\n      <li>Cafonate (LK, PH);</li>\n      <li>Calcium Folinate (NZ);</li>\n      <li>Calciumfolinat Faulding (SE);</li>\n      <li>Calciumfolinat Pharmalink (SE);</li>\n      <li>Calciumfolinat &rdquo;Faulding&rdquo; (DK);</li>\n      <li>Calciumfolinat-Ebewe (PL, TW);</li>\n      <li>Calfonat (DK);</li>\n      <li>Dalisol (MX);</li>\n      <li>Estroquin (PE);</li>\n      <li>Ferbon (KR);</li>\n      <li>Folcasin (ID);</li>\n      <li>Folical (CO);</li>\n      <li>Folina 15 (TW);</li>\n      <li>Folinato de Calcio Dakota Farma (PT);</li>\n      <li>Kalcij-folinat (HR);</li>\n      <li>Kunyrin (VN);</li>\n      <li>Lederfolin (ES, IE, IT);</li>\n      <li>Lederfoline (FR, PT);</li>\n      <li>Ledervorin Calcium (BE, LU, NL);</li>\n      <li>Leucan (ID);</li>\n      <li>Leucocalcin (PY);</li>\n      <li>Leuconolver (VE);</li>\n      <li>Leucovorin (AE, AT, BG, CH, DE, EG, GR, IE, IL, JO, KW, LB, PL, SA, TH, UY);</li>\n      <li>Leucovorin Ca (PL);</li>\n      <li>Leucovorin Calcium (AU, BB, CZ, HK, HN, ID, IN, MY, NZ, TH);</li>\n      <li>Leucovorine Abic (NL);</li>\n      <li>Lifacor (PH);</li>\n      <li>Likelin (CN);</li>\n      <li>Lovorin (PH);</li>\n      <li>Medifolin (PT);</li>\n      <li>Medsavorina (MX);</li>\n      <li>MPL Coverin (PH);</li>\n      <li>Novorin (ID);</li>\n      <li>Nyrin (SG);</li>\n      <li>Refolinon (GB, LU);</li>\n      <li>Rescuvolin (BE, CH, DK, GR, KR, LU, SE, TH, TW);</li>\n      <li>Robin (KR);</li>\n      <li>Rontafur (AR);</li>\n      <li>Tecnovorin (BR, EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barceloux DG, Bond GR, Krenzelok EP, et al, &quot;American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning,&quot; <i>J Toxicol Clin Toxicol</i>, 2002, 40(4):415-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12216995/pubmed\" target=\"_blank\" id=\"12216995\">12216995</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. <i>Cancer</i>. 1978;41(1):36-51. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/342086 /pubmed\" target=\"_blank\" id=\"342086 \">342086 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA. Therapeutic monitoring of methotrexate and other antineoplastic drugs. In Baer DM, Devits WR eds. <i>Interpretations in Therapeutic Drug Monitoring</i>. Chicago, IL: American Society of Clinical Pathology; 1981:169-181.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djukic A. Folate-responsive neurologic diseases. <i>Pediatr Neurol</i>. 2007;37(6):387-397. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18021918 /pubmed\" target=\"_blank\" id=\"18021918 \">18021918 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frye RE, Donner E, Golja A, Rooney CM. Folinic acid-responsive seizures presenting as breakthrough seizures in a 3-month-old boy. <i>J Child Neurol</i>. 2003;18(8):562-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/13677584 /pubmed\" target=\"_blank\" id=\"13677584 \">13677584 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. <i>Ann Neurol</i>. 2009;65(5):550-556.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jardine LF, Ingram LC, and Bleyer WA, &quot;Intrathecal Leucovorin After Intrathecal Methotrexate Overdose,&quot; <i>J Pediatr Hematol Oncol</i>, 1996, 18(3):302-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/8689347/pubmed\" target=\"_blank\" id=\"8689347\">8689347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium for injection [prescribing information]. Schaumberg, IL: Sagent Pharmaceuticals; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leucovorin calcium tablets [prescribing information]. Columbus, OH: Roxane Laboratories, Inc; December 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McAuley JB. Toxoplasmosis in children. <i>Pediatr Infect Dis J</i>. 2008;27(2):161-162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18227714 /pubmed\" target=\"_blank\" id=\"18227714 \">18227714 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. <i>Pediatr Neurol</i>. 2006;34(2):164-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16458834 /pubmed\" target=\"_blank\" id=\"16458834 \">16458834 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SW and Nelson LS, &quot;Case Files of the New York City Poison Control Center: Antidotal Strategies for the Management of Methotrexate Toxicity,&quot; <i>J Med Toxicol</i>, 2008, 4(2):132-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18570175/pubmed\" target=\"_blank\" id=\"18570175\">18570175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/19747629 /pubmed\" target=\"_blank\" id=\"19747629 \">19747629 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. <i>J Child Neurol</i>. 1999;14(8):529-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10456764 /pubmed\" target=\"_blank\" id=\"10456764 \">10456764 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC and Adamson PC, &quot;Understanding and Managing Methotrexate Nephrotoxicity,&quot; <i>Oncologist</i>, 2006, 11(6):694-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16794248/pubmed\" target=\"_blank\" id=\"16794248\">16794248</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12544 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F11508393\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1059685\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F26536218\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1059679\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187344\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187331\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1059689\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187359\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1059688\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187410\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187407\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187350\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5524355\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299583\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187338\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187340\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5524281\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1059684\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187334\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187349\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F12807804\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524636\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187352\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12544|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=leucovorin-drug-information\" class=\"drug drug_general\">Leucovorin: Drug information</a></li><li><a href=\"topic.htm?path=leucovorin-patient-drug-information\" class=\"drug drug_patient\">Leucovorin: Patient drug information</a></li></ul></div></div>","javascript":null}